Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30234855 | 1.00 | GBA1 (0.33) | GBA1PREPPOLBTGM2MET | |
| SCHEMBL23369065 | 0.91 | GBA1 (0.40) | GBA1POLBTGM2METGPR119 | |
| SCHEMBL20138766 | 0.88 | GBA1 (0.38) | GBA1PREPPOLBMETGPR119 | |
| SCHEMBL29470074 | 0.86 | GPR119 (0.38) | POLBGPR119 | |
| SCHEMBL20154070 | 0.86 | GPR119 (0.38) | POLBGPR119 | |
| SCHEMBL20139182 | 0.85 | POLB (0.30) | POLB | |
| SCHEMBL20143003 | 0.79 | POLB (0.34) | GBA1PREPPOLBMETGPR119 | |
| SCHEMBL23369067 | 0.77 | GBA1 (0.47) | GBA1POLBMETGPR119 | |
| SCHEMBL30234844 | 0.74 | GPR119 (0.41) | GBA1POLBGPR119 | |
| SCHEMBL20154071 | 0.74 | GPR119 (0.41) | GBA1POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | GBA1 3480/4885PREP 1386/4885POLB 254/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | GBA1 3480/4885PREP 1386/4885POLB 254/4885 |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | GBA1 3480/4885PREP 1386/4885POLB 254/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | GBA1 3480/4885PREP 1386/4885POLB 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.